Altimmune to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in May 2022:

• H.C. Wainwright Global Investment Conference
  Tuesday, May 24, 2022
  7:00 am Eastern Time
  The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

• B. Riley Securities Institutional Investor Conference
  Thursday, May 26, 2022
  1:00 pm Pacific Time
  The session will be an in person fireside chat.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com